Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multinational, three-arm, randomized, double-blind, placebo-controlled Phase 2b clinical study of NP-120 (Ifenprodil) for the treatment of refractory chronic cough

Next Previous
X
Search
Trial Profile

A multinational, three-arm, randomized, double-blind, placebo-controlled Phase 2b clinical study of NP-120 (Ifenprodil) for the treatment of refractory chronic cough

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 19 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ifenprodil (Primary)
  • Indications Cough
  • Focus Therapeutic Use
  • Acronyms SILINDA
  • Sponsors Algernon Pharmaceuticals; Seyltx

    • Most Recent Events

    • 16 Jul 2024 According to a Seyltx Inc media release, full results of the study will be presented at the London International Cough Symposium July 18th to 19th, 2024.
    • 16 Jul 2024 According to a Seyltx Inc media release, design for this study unveiled by the company and first patient enrollment expected in early 2025. Topline data from SILINDA are expected approximately at the end of 2026.
    • 09 Jul 2024 According to a Seyltx Inc media release, today announced the results of a study performed that analyzed real world electronic health record (EHR) data and Based on this data, company will optimize enrollment in its Phase 2b clinical trial and more accurately model the commercial opportunity for a product candidate. The study is expected to have the first patient enrolled in 2025.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top